UA100005C2 - Ингибиторы репликации вируса иммунодефицита человека - Google Patents
Ингибиторы репликации вируса иммунодефицита человекаInfo
- Publication number
- UA100005C2 UA100005C2 UAA200813831A UAA200813831A UA100005C2 UA 100005 C2 UA100005 C2 UA 100005C2 UA A200813831 A UAA200813831 A UA A200813831A UA A200813831 A UAA200813831 A UA A200813831A UA 100005 C2 UA100005 C2 UA 100005C2
- Authority
- UA
- Ukraine
- Prior art keywords
- immunodeficiency virus
- human immunodeficiency
- inhibitors
- virus replication
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/12—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 3 and unsubstituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/14—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 6 and unsubstituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
В заявке описаны соединения формулы (I)их производные, которые содержат метку, поддающуюся обнаружению, их композиции и их применение для борьбы с инфицированием людей вирусом иммунодефицита человека (ВИЧ).В заявке также описаны новые ингибиторы репликации ВИЧ, фармацевтические композиции, которые содержат такие соединения, и применение этих соединений для борьбы с инфицированием ВИЧ.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74731106P | 2006-05-16 | 2006-05-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
UA100005C2 true UA100005C2 (ru) | 2012-11-12 |
Family
ID=38693497
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA200813831A UA100005C2 (ru) | 2006-05-16 | 2007-05-14 | Ингибиторы репликации вируса иммунодефицита человека |
Country Status (34)
Country | Link |
---|---|
US (1) | US7939545B2 (ru) |
EP (1) | EP2019825B9 (ru) |
JP (3) | JP5144649B2 (ru) |
KR (1) | KR20090007755A (ru) |
CN (1) | CN101448812B (ru) |
AR (1) | AR060949A1 (ru) |
AT (1) | ATE479673T1 (ru) |
AU (1) | AU2007250427B2 (ru) |
BR (1) | BRPI0711642A2 (ru) |
CA (1) | CA2650798C (ru) |
CL (1) | CL2007001392A1 (ru) |
DE (1) | DE602007008874D1 (ru) |
DK (1) | DK2019825T3 (ru) |
EA (1) | EA018655B1 (ru) |
EC (1) | ECSP088784A (ru) |
ES (1) | ES2352576T3 (ru) |
HK (1) | HK1131153A1 (ru) |
HR (1) | HRP20100553T1 (ru) |
IL (1) | IL195244A0 (ru) |
ME (1) | ME01217B (ru) |
MX (1) | MX2008014459A (ru) |
MY (1) | MY148534A (ru) |
NO (1) | NO20084081L (ru) |
NZ (1) | NZ573526A (ru) |
PE (1) | PE20080093A1 (ru) |
PL (1) | PL2019825T3 (ru) |
PT (1) | PT2019825E (ru) |
RS (1) | RS51465B (ru) |
SI (1) | SI2019825T1 (ru) |
TW (1) | TWI406856B (ru) |
UA (1) | UA100005C2 (ru) |
UY (1) | UY30350A1 (ru) |
WO (1) | WO2007131350A1 (ru) |
ZA (1) | ZA200808022B (ru) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050075279A1 (en) * | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
US7939545B2 (en) * | 2006-05-16 | 2011-05-10 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
EP2220095B1 (en) * | 2007-11-15 | 2013-01-02 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
JP5269086B2 (ja) * | 2007-11-15 | 2013-08-21 | ギリアード サイエンシス インコーポレーテッド | ヒト免疫不全ウイルスの複製阻害薬 |
UA100250C2 (ru) * | 2007-11-16 | 2012-12-10 | Гілеад Сайнсіз, Інк. | Ингибиторы репликации вируса иммунодефицита человека |
EP2220084B1 (en) * | 2007-11-16 | 2014-02-19 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
GB0908394D0 (en) | 2009-05-15 | 2009-06-24 | Univ Leuven Kath | Novel viral replication inhibitors |
US8338441B2 (en) * | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
GB0913636D0 (en) | 2009-08-05 | 2009-09-16 | Univ Leuven Kath | Novel viral replication inhibitors |
WO2011133707A2 (en) | 2010-04-23 | 2011-10-27 | Kineta, Inc. | Anti-viral compounds |
JP5806735B2 (ja) * | 2010-07-02 | 2015-11-10 | ギリアード サイエンシーズ, インコーポレイテッド | Hiv抗ウイルス化合物としての2−キノリニル−酢酸誘導体 |
CA2802308C (en) | 2010-07-02 | 2018-08-28 | Lianhong Xu | Napht-2-ylacetic acid derivatives to treat aids |
US8633200B2 (en) | 2010-09-08 | 2014-01-21 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
JP2013542243A (ja) | 2010-11-15 | 2013-11-21 | カトリーケ ウニヴェルシテイト ルーヴェン | 新規な抗ウイルス性化合物 |
TW201302761A (zh) | 2011-04-04 | 2013-01-16 | Gilead Sciences Inc | Hiv抑制劑之固態形式 |
JP2014511859A (ja) * | 2011-04-04 | 2014-05-19 | ギリアード サイエンシーズ, インコーポレイテッド | Hivインテグラーゼ阻害剤の調製のためのプロセス |
EP2508511A1 (en) | 2011-04-07 | 2012-10-10 | Laboratoire Biodim | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
EP2511273B8 (en) * | 2011-04-15 | 2019-06-26 | Hivih | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
MX2013012266A (es) * | 2011-04-21 | 2013-11-22 | Gilead Sciences Inc | Compuestos de benzotiazol y su uso farmaceutico. |
WO2013002357A1 (ja) * | 2011-06-30 | 2013-01-03 | 塩野義製薬株式会社 | Hiv複製阻害剤 |
US8791108B2 (en) | 2011-08-18 | 2014-07-29 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
US9199959B2 (en) | 2011-10-25 | 2015-12-01 | Shionogi & Co., Ltd. | HIV replication inhibitor |
WO2013073875A1 (ko) * | 2011-11-15 | 2013-05-23 | 한국화학연구원 | 신규한 항바이러스성 피롤로피리딘 유도체 및 이의 제조방법 |
WO2013103724A1 (en) * | 2012-01-04 | 2013-07-11 | Gilead Sciences, Inc. | 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids |
US9284323B2 (en) | 2012-01-04 | 2016-03-15 | Gilead Sciences, Inc. | Naphthalene acetic acid derivatives against HIV infection |
US8629276B2 (en) | 2012-02-15 | 2014-01-14 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
US9034882B2 (en) | 2012-03-05 | 2015-05-19 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
US9006235B2 (en) | 2012-03-06 | 2015-04-14 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
MD20140063A2 (ru) | 2012-04-20 | 2014-12-31 | Gilead Sciences, Inc. | Производные бензотиазол-6-ил уксусной кислоты и их применение для лечения инфекции ВИЧ |
US8906929B2 (en) | 2012-08-16 | 2014-12-09 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
WO2014055618A1 (en) | 2012-10-03 | 2014-04-10 | Gilead Sciences, Inc. | Solid state forms of hiv inhibitor: hemi-succinate of (2s)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid) |
US20140094609A1 (en) * | 2012-10-03 | 2014-04-03 | Gilead Sciences, Inc. | Process for the preparation of an hiv integrase inhibitor |
EP2716639A1 (en) | 2012-10-05 | 2014-04-09 | Laboratoire Biodim | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
EP2716632A1 (en) | 2012-10-05 | 2014-04-09 | Laboratoire Biodim | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
EP2719685A1 (en) * | 2012-10-11 | 2014-04-16 | Laboratoire Biodim | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
TW201441197A (zh) | 2013-01-31 | 2014-11-01 | Shionogi & Co | Hiv複製抑制劑 |
CN105189510B (zh) | 2013-03-13 | 2017-05-17 | 百时美施贵宝公司 | 人免疫缺陷病毒复制的抑制剂 |
US9580431B2 (en) | 2013-03-13 | 2017-02-28 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
EP2970273B1 (en) | 2013-03-13 | 2017-03-01 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
JP6268656B2 (ja) | 2013-03-14 | 2018-01-31 | ビーブ・ヘルスケア・ユーケイ・(ナンバー5)・リミテッドViiV Healthcare UK (No.5) Limited | ヒト免疫不全ウイルス複製の阻害剤 |
WO2014159959A1 (en) | 2013-03-14 | 2014-10-02 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
EP2821082A1 (en) | 2013-07-05 | 2015-01-07 | Laboratoire Biodim | Method of producing an inactivated lentivirus, especially HIV, vaccine, kit and method of use |
EP2821104A1 (en) * | 2013-07-05 | 2015-01-07 | Laboratoire Biodim | Inhibitors of viral replication, their process of preparation and their therapeutical uses |
WO2015123230A1 (en) | 2014-02-12 | 2015-08-20 | Bristol-Myers Squibb Company | Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication |
US9409922B2 (en) | 2014-02-18 | 2016-08-09 | Bristol-Myers Squibb Company | Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication |
WO2015126743A1 (en) | 2014-02-18 | 2015-08-27 | Bristol-Myers Squibb Company | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication |
EP3116879A1 (en) | 2014-02-18 | 2017-01-18 | VIIV Healthcare UK (No.5) Limited | Imidazopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication |
WO2015126765A1 (en) | 2014-02-19 | 2015-08-27 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
US9273067B2 (en) | 2014-02-19 | 2016-03-01 | Bristol-Myers Squibb Company | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication |
EP3116880B1 (en) | 2014-02-20 | 2018-03-21 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid macrocycles as inhibitors of human immunodeficiency virus replication |
US9193720B2 (en) | 2014-02-20 | 2015-11-24 | Bristol-Myers Squibb Company | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
JP6579549B2 (ja) | 2014-05-16 | 2019-09-25 | 塩野義製薬株式会社 | Hiv複製阻害作用を有する3環性複素環誘導体 |
WO2016012913A1 (en) * | 2014-07-21 | 2016-01-28 | Viiv Healthcare Uk Limited | Phenyl and tertbutylacetic acid substituted pyridinones having anti-hiv effects |
CA2987384A1 (en) | 2015-05-29 | 2016-12-08 | Shionogi & Co., Ltd. | Nitrogen-containing tricyclic derivative having hiv replication inhibitory activity |
US20180170903A1 (en) | 2015-07-06 | 2018-06-21 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
US10221156B2 (en) | 2015-07-08 | 2019-03-05 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
KR20180025916A (ko) | 2015-07-09 | 2018-03-09 | 비브 헬스케어 유케이 (넘버5) 리미티드 | 인간 면역결핍 바이러스 복제의 억제제로서의 피리딘-3-일 아세트산 유도체 |
CN107820492A (zh) | 2015-07-09 | 2018-03-20 | Viiv保健英国第五有限公司 | 作为人类免疫缺陷病毒复制抑制剂的吡啶‑3‑基乙酸衍生物 |
KR20180035910A (ko) | 2015-08-07 | 2018-04-06 | 비브 헬스케어 유케이 (넘버5) 리미티드 | 인간 면역결핍 바이러스 복제의 억제제로서 피리딘-3-일 아세트산 유도체 |
CN108026113A (zh) | 2015-08-10 | 2018-05-11 | Viiv保健英国第五有限公司 | 作为人免疫缺陷病毒复制的抑制剂的咪唑并吡啶大环类化合物 |
AR105653A1 (es) | 2015-08-11 | 2017-10-25 | VIIV HEALTHCARE UK (Nº 5) LTD | Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana |
TW201718537A (zh) | 2015-08-12 | 2017-06-01 | Viiv醫療保健英國(No.5)有限公司 | 做為人類免疫缺陷病毒複製抑制劑之吡啶-3-基乙酸衍生物 |
JP2018522913A (ja) | 2015-08-12 | 2018-08-16 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤としての5−(n−[6,5]−縮合二環式アリールテトラヒドロイソキノリン−6−イル)ピリジン−3−イル酢酸誘導体 |
CA2995087A1 (en) | 2015-08-12 | 2017-02-16 | John F. Kadow | 5-(n-fused tricyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
BR112018003181A2 (pt) | 2015-08-20 | 2018-09-25 | Viiv Healthcare Uk No 5 Ltd | composto, composição, e, método para tratar infecção por hiv |
JP2019515003A (ja) | 2016-05-11 | 2019-06-06 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−3−イル酢酸誘導体 |
US20200325127A1 (en) | 2016-05-11 | 2020-10-15 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
EP3455214A1 (en) | 2016-05-11 | 2019-03-20 | ViiV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
JP2020503352A (ja) | 2017-01-03 | 2020-01-30 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−3−イル酢酸誘導体 |
TW201835068A (zh) | 2017-01-03 | 2018-10-01 | 英商Viiv醫療保健英國(No.5)有限公司 | 作為人類免疫缺乏病毒複製之抑制劑之吡啶-3-基乙酸衍生物 |
WO2019244066A2 (en) | 2018-06-19 | 2019-12-26 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
WO2020003093A1 (en) | 2018-06-25 | 2020-01-02 | VIIV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6463518A (en) * | 1987-09-02 | 1989-03-09 | Otsuka Pharma Co Ltd | Antiarrhythmic agent |
JPH03227923A (ja) | 1990-01-30 | 1991-10-08 | Sawai Seiyaku Kk | ひと免疫不全ウイルス疾患処置剤 |
US5304554A (en) * | 1990-04-27 | 1994-04-19 | Emory University | 4-[(alkyl or dialkyl)amino]quinolines and their method of preparation |
DE4208304A1 (de) * | 1992-03-16 | 1993-09-23 | Merck Patent Gmbh | 2-oxochinolinderivate |
US5482967A (en) * | 1992-09-04 | 1996-01-09 | Takeda Chemical Industries, Ltd. | Condensed heterocyclic compounds, their production and use |
IL108459A0 (en) * | 1993-02-05 | 1994-04-12 | Opjohn Company | 4-Hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl [B] pyran-2-ones useful for treating infections due to hiv and other retroviruses |
DE19528418A1 (de) * | 1995-08-02 | 1997-02-06 | Merck Patent Gmbh | Endothelin-Rezeptor-Antagonisten |
IT1289238B1 (it) * | 1996-12-10 | 1998-09-29 | Bio S S P A Ora Bio S S R L | Composizioni farmaceutiche per il trattamento di infezioni virali comprendenti una 4 arilcumarina |
FR2772761B1 (fr) | 1997-12-23 | 2000-05-26 | Lipha | Nouveaux derives de n-phenylamide et n-pyridylamide, leur procede de preparation et compositions pharmaceutiques les contenant |
BR9915744A (pt) * | 1998-12-04 | 2001-08-21 | Bristol Myers Squibb Co | Derivados 4-arilquinolin-2-ona 3-substituìdos como moduladores do canal de potássio |
US6777413B2 (en) | 2000-02-01 | 2004-08-17 | Millennium Pharmaceuticals, Inc. | 2-[1H]-quinolone and 2-[1H]-quinoxalone inhibitors of factor Xa |
DE10155076A1 (de) * | 2001-11-09 | 2003-05-22 | Merck Patent Gmbh | Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen |
BRPI0417543A (pt) | 2003-12-12 | 2007-03-27 | Wyeth Corp | quinolinas úteis no tratamento de doença cardiovascular |
US7939545B2 (en) * | 2006-05-16 | 2011-05-10 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
-
2007
- 2007-05-09 US US11/746,303 patent/US7939545B2/en active Active
- 2007-05-14 RS RSP-2010/0443A patent/RS51465B/en unknown
- 2007-05-14 EA EA200802209A patent/EA018655B1/ru not_active IP Right Cessation
- 2007-05-14 MY MYPI20084560A patent/MY148534A/en unknown
- 2007-05-14 DE DE602007008874T patent/DE602007008874D1/de active Active
- 2007-05-14 PT PT07784947T patent/PT2019825E/pt unknown
- 2007-05-14 JP JP2009510243A patent/JP5144649B2/ja active Active
- 2007-05-14 BR BRPI0711642-0A patent/BRPI0711642A2/pt not_active IP Right Cessation
- 2007-05-14 ME MEP-2010-192A patent/ME01217B/me unknown
- 2007-05-14 MX MX2008014459A patent/MX2008014459A/es active IP Right Grant
- 2007-05-14 CA CA2650798A patent/CA2650798C/en not_active Expired - Fee Related
- 2007-05-14 CN CN200780017997XA patent/CN101448812B/zh not_active Expired - Fee Related
- 2007-05-14 NZ NZ573526A patent/NZ573526A/en not_active IP Right Cessation
- 2007-05-14 UA UAA200813831A patent/UA100005C2/ru unknown
- 2007-05-14 SI SI200730411T patent/SI2019825T1/sl unknown
- 2007-05-14 EP EP07784947A patent/EP2019825B9/en active Active
- 2007-05-14 DK DK07784947.9T patent/DK2019825T3/da active
- 2007-05-14 KR KR1020087027963A patent/KR20090007755A/ko active IP Right Grant
- 2007-05-14 ES ES07784947T patent/ES2352576T3/es active Active
- 2007-05-14 AT AT07784947T patent/ATE479673T1/de active
- 2007-05-14 WO PCT/CA2007/000845 patent/WO2007131350A1/en active Application Filing
- 2007-05-14 AU AU2007250427A patent/AU2007250427B2/en not_active Ceased
- 2007-05-14 PL PL07784947T patent/PL2019825T3/pl unknown
- 2007-05-15 CL CL2007001392A patent/CL2007001392A1/es unknown
- 2007-05-15 TW TW096117144A patent/TWI406856B/zh not_active IP Right Cessation
- 2007-05-15 UY UY30350A patent/UY30350A1/es not_active Application Discontinuation
- 2007-05-15 PE PE2007000583A patent/PE20080093A1/es not_active Application Discontinuation
- 2007-05-16 AR ARP070102105A patent/AR060949A1/es not_active Application Discontinuation
-
2008
- 2008-09-18 ZA ZA200808022A patent/ZA200808022B/xx unknown
- 2008-09-25 NO NO20084081A patent/NO20084081L/no not_active Application Discontinuation
- 2008-09-30 EC EC2008008784A patent/ECSP088784A/es unknown
- 2008-11-12 IL IL195244A patent/IL195244A0/en unknown
-
2009
- 2009-12-01 HK HK09111260.1A patent/HK1131153A1/xx not_active IP Right Cessation
-
2010
- 2010-10-12 HR HR20100553T patent/HRP20100553T1/hr unknown
-
2012
- 2012-11-22 JP JP2012256668A patent/JP5530506B2/ja active Active
-
2014
- 2014-04-18 JP JP2014086731A patent/JP2014139242A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA100005C2 (ru) | Ингибиторы репликации вируса иммунодефицита человека | |
MX2010005292A (es) | Inhibidores de la replicacion del virus de la inmunodeficiencia humana. | |
MXPA05008368A (es) | 1,2,4-triazinas inhibidoras del virus de inmunodeficiencia humana. | |
BR112012018670A2 (pt) | combinação, uso de um composto, composição farmacêutica, e, pacote de paciente | |
UA95715C2 (ru) | Фосфадиазиновые производные, фармацевтическая композиция и их применение | |
NZ585226A (en) | Inhibitors of human immunodeficiency virus replication | |
BRPI0507628A (pt) | composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma infecção viral em um ser humano, uso de um composto composição farmacêutica, e, processo para a preparação de um composto | |
NO20084256L (no) | DPP IV inhibitorformuleringer | |
IL207468A (en) | HCV inhibitors and their use in the preparation of medicines for the treatment of HCV infections | |
HRP20050103A2 (en) | N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion | |
TW200621737A (en) | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | |
MY145647A (en) | (4-hydroxy-2-oxo-3h-benzothiazol-7-yl)ethylamine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy (for example in the treatment of respiratory disease states) | |
MX2009014235A (es) | 4-bencilaminoquinolonas, composiciones farmaceuticas que las contiene y su uso. | |
MX2009013501A (es) | Compuestos piperidinicos y sus usos. | |
MX2010009022A (es) | Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso. | |
TW200639156A (en) | New compounds | |
UA104988C2 (ru) | Производные пирониндола и способ их получения | |
TW200626158A (en) | Naphthaline derivatives | |
MX2009006010A (es) | Derivados de amina y su uso en enfermedades mediadas por el adrenoreceptor beta 2. | |
DE602004008959D1 (de) | Benzoäbüä1,4üdioxepinderivate | |
BRPI0509667B8 (pt) | composto, processo para a preparação de um composto de fórmula (i), medicamento e uso de um composto | |
TW200635925A (en) | Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents | |
IL191670A0 (en) | Compounds for the inhibition of apoptosis | |
DE602007004348D1 (de) | Arzneimittel zur behandlung von sarkoglykanopathien | |
GB0615105D0 (en) | Novel compounds |